Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silexan phase III trial in mixed anxiety and depressive disorder
2012-000438-21Phase 3Completed
- Sponsor
- Schwabe Group
- Start
- Jul 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mixed anxiety-depressive disorder comparing Silexan with Placebo (2 arms). Primary endpoints: Change in HAMA total score and Change in MADRS total score. Started Jul 2012; status: completed.
02
Drugs
Silexan
03
Conditions
mixed anxiety-depressive disorder
Beyond the preview
Go deeper on 2012-000438-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000438-21.